kura-8k_20200624.htm
false 0001422143 0001422143 2020-06-24 2020-06-24 0001422143 dei:FormerAddressMember 2020-06-24 2020-06-24

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 24, 2020

 

KURA ONCOLOGY, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37620

61-1547851

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

12730 High Bluff Drive, Suite 400, San Diego, CA

 

92130

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 500-8800

3033 Science Park Road, Suite 220, San Diego, CA 92121

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

KURA

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 24, 2020, Kura Oncology, Inc. held its Annual Meeting of Stockholders (the “Annual Meeting”). As of the close of business on April 27, 2020, the record date for the Annual Meeting, there were 45,433,279 shares of common stock outstanding, of which 37,407,261 shares of common stock were present in person or represented by proxy at the Annual Meeting. 

At the Annual Meeting, stockholders:

(1) elected Steven H. Stein, M.D., Mary T. Szela and Diane Parks as Class III directors to hold office until the 2023 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal;

(2) ratified the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;

(3) approved, on an advisory basis, the compensation paid to our named executive officers as disclosed in the proxy statement; and

(4) approved, on an advisory basis, the recommended frequency of solicitation of stockholder advisory approval of executive compensation every year.

The following sets forth detailed information regarding the final results of the voting for the Annual Meeting:

Proposal 1. Election of Directors

Name of Director Elected

 

For

 

 

Withheld

 

 

Broker Non-Votes

 

Steven H. Stein, M.D.

 

 

26,639,903

 

 

 

8,035,858

 

 

 

2,731,500

 

Mary T. Szela

 

 

32,058,336

 

 

 

2,617,425

 

 

 

2,731,500

 

Diane Parks

 

 

32,169,154

 

 

 

2,506,607

 

 

 

2,731,500

 

Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm

For

 

 

Against

 

 

Abstain

 

 

Broker Non-Votes

 

 

34,996,944

 

 

 

30,258

 

 

 

2,380,059

 

 

 

 

Proposal 3. Advisory Vote on Executive Compensation

For

 

 

Against

 

 

Abstain

 

 

Broker Non-Votes

 

 

31,232,759

 

 

 

1,059,555

 

 

 

2,383,447

 

 

 

2,731,500

 

Proposal 4. Advisory Vote on the Frequency of Solicitation of Stockholder Advisory Approval of Executive Compensation

1 Year

 

 

2 Years

 

 

3 Years

 

 

Abstain

 

 

Broker Non-Votes

 

 

31,481,954

 

 

 

6,878

 

 

 

802,100

 

 

 

2,384,829

 

 

 

2,731,500

 

 


 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

KURA ONCOLOGY, INC.

 

 

 

 

Date: June 26, 2020

 

By:

/s/ James Basta

 

 

 

James Basta

 

 

 

Chief Legal Officer

 

 

 

v3.20.1
Document and Entity Information
Jun. 24, 2020
Document And Entity Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 24, 2020
Entity Registrant Name KURA ONCOLOGY, INC.
Entity Central Index Key 0001422143
Entity Emerging Growth Company false
Entity File Number 001-37620
Entity Tax Identification Number 61-1547851
Entity Incorporation State Country Code DE
Entity Address, Address Line One 12730 High Bluff Drive
Entity Address, Address Line Two Suite 400
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code (858)
Local Phone Number 500-8800
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol KURA
Security Exchange Name NASDAQ
Former Address  
Document And Entity Information [Line Items]  
Entity Address, Address Line One 3033 Science Park Road
Entity Address, Address Line Two Suite 220
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121